Core Insights - Altimmune, Inc. is set to present 24-week efficacy and safety data from its Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) at The Liver Meeting 2025 [1][4] - The company anticipates announcing 48-week data in Q4 2025, indicating ongoing development and potential for further insights into the treatment's effectiveness [4] Presentation Details - The late-breaking presentations will focus on the recent 24-week data readout from the IMPACT Phase 2b trial [4] - A poster will feature AI-based analyses of liver fibrosis reduction, showcasing innovative approaches in the study [1][8] Study Overview - The IMPACT trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive weekly subcutaneous pemvidutide doses of either 1.2 mg, 1.8 mg, or placebo for 24 weeks [5] - Key efficacy endpoints include MASH resolution without worsening of fibrosis and fibrosis improvement without worsening of MASH at 24 weeks, with secondary endpoints focusing on weight loss and non-invasive tests of fibrosis [5] About Pemvidutide - Pemvidutide is a novel peptide-based dual receptor agonist targeting GLP-1 and glucagon receptors, aimed at treating MASH, Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD) [6] - The FDA has granted Fast Track designations for pemvidutide in both MASH and AUD, highlighting significant unmet medical needs in these areas [6] Company Background - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, with pemvidutide as its lead product candidate [9]

Core Viewpoint - ALT5 Sigma Corporation will participate in the A.G.P. Digital Assets & Technology Showcase on October 8, 2025, highlighting its role in the digital asset treasury sector [1] Company Participation - The presentation will feature Jonathan Hugh, Chief Financial Officer of ALT5 Sigma, indicating the company's commitment to engaging with industry stakeholders [1] - Other notable participants include Zak Folkman, Co-Founder of World Liberty Financial, and Matt Morgan, Advisor to World Liberty Financial, showcasing a collaborative approach within the digital asset space [1]

Core Points - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against the company [2][3] Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction, despite prior inflated expectations [4] - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [5]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for alleged inflated expectations regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [8]. Allegation Details - The lawsuit claims that Altimmune failed to achieve statistical significance in the primary endpoint of fibrosis reduction in the trial, despite previously optimistic projections [8]. - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 to $3.61, a decrease of 53.2% in one day [8]. Next Steps - Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4][8].

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the results of its IMPACT Phase 2b MASH trial for Pemvidutide, which led to a significant drop in its stock price following the announcement of trial results that did not meet statistical significance [1][2]. Group 1: Allegations and Impact - The class action is based on a complaint that claims Altimmune provided inflated expectations prior to the announcement of the trial results on June 26, 2025 [1]. - The trial results showed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction, attributed to a higher-than-expected placebo response [1]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of ALT during the specified class period are encouraged to register for the class action by October 6, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6][7] Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Altimmune to contact them to discuss their legal options [1][9] - There is a deadline of October 6, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Altimmune [4][8] Group 2: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [6] - The stock price of Altimmune fell from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [7]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [8]. Allegation Details - The lawsuit claims that Altimmune provided inflated expectations prior to the announcement of the trial results, which revealed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction [8]. - Following the announcement on June 26, 2025, Altimmune's stock price plummeted from $7.71 to $3.61, marking a 53.2% decline in one day [8]. Next Steps - Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4][8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, urging affected investors to discuss their legal options [1][3][4]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company involved in developing treatments, including Pemvidutide for MASH [3]. - The company faced a setback when it failed to achieve statistical significance in its Phase 2b MASH trial, leading to inflated expectations prior to the announcement [3]. Group 2: Stock Performance - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [4]. Group 3: Legal Actions - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Altimmune, Inc. between August 10, 2023, and June 25, 2025, about the upcoming lead plaintiff deadline on October 6, 2025, for a class action lawsuit related to alleged securities fraud [1]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 6, 2025 [2]. - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, leading to inflated expectations and subsequent investor damages when the true results were revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [3].

Core Points - A class action securities lawsuit has been filed against Altimmune, Inc. for alleged securities fraud affecting investors between August 10, 2023, and June 25, 2025 [1] - The lawsuit follows a significant decline in Altimmune's stock price after the announcement of disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, where the primary endpoint of fibrosis reduction did not achieve statistical significance [2] - Investors who suffered losses during the relevant time frame have until October 6, 2025, to request to be appointed as lead plaintiff, with no out-of-pocket costs to participate in the class action [3] Company Details - On June 26, 2025, Altimmune reported that the IMPACT Phase 2b MASH trial did not meet the expected statistical significance for fibrosis reduction, leading to a 53.2% drop in stock price from $7.71 to $3.61 per share in one day [2] - The company attributed the disappointing results to the Phase 2 nature of the trial and expressed hope for better outcomes in the upcoming Phase 3 trial [2] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]